Recent guidelines for starting anti-retroviral therapy recommend that patients with advanced disease, as manifested by the development of an AIDS-defining illness including HAD, or presence of severe symptoms such as unexplained fever, persistent diarrhea, or unexplained weight loss, should be started on ART if their \(\mathrm{CD}^{*} \mathrm{~T}\) cell count is \(<\mathbf{1 0 0}\). True/False

Short Answer

Expert verified
Answer: True

Step by step solution

01

Read the statement carefully

Read and comprehend the statement about recent guidelines for starting anti-retroviral therapy (ART) for patients with advanced disease.
02

Evaluate the statement

Determine if the provided statement is true or not. To do this, assess if the recommendation for starting ART for patients with advanced disease corresponds to the actual—recent guidelines, including starting ART when the CD+ T count is below 100. It is vital for the student to be familiar with recent guidelines or to look up the latest information on ART treatment recommendations.
03

Provide the answer

Since the statement is in line with recent guidelines (which can vary by source), the answer is True. However, it is essential to stay updated with current guidelines to ensure the correct information at all times.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with Vaia!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

See all solutions

Recommended explanations on Biology Textbooks

View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free